Neisseria gonorrhoea infection is the second most common sexually transmitted disease worldwide as per the classification of the Centre of Disease Prevention [1], and is of increasing concern due to the rise in resistance to the current antimicrobials. Humans are found to be the only host specific for N. gonorrhoea infection, which affects the mucosal surface of the cervix in females and urethra in males as well as occasionally affecting the eyes of newborn babies (conjunctivitis) through vertical transmission during birth from infected birth canals [2]. Recently, N. gonorrhoea isolates around the world have been found to be resistant to the last line of dual-treatment therapy of ceftriaxone and azithromycin [3]. N. gonorrhoea have therefore been classified as a high priority pathogen needing new antibiotics as per the World Health Organization [4].This project will help address the need for new antimicrobial compounds by tracking the efficacy of novel antimicrobial compounds and treatments using bioluminescent imaging using a bioluminescent strain of N. gonorrhoea. This strain will be constructed by chromosomal insertion of the luxABCDE gene operon through transformation, resulting in the expression of luciferase enzyme during metabolically active growth conditions, like those found in pathogenic infections. Bacteria expressing luciferase enzyme will be confirmed genotypically by sequencing and phenotypically by bioluminescence imaging. The efficacy of different antimicrobial compounds will be studied in several bacterial infection models using the bioluminescent bacteria, where the bioluminescence allows real time evaluation of bacterial quantity and avoid tedious traditional measurements of the number of bacteria present. The bioluminescent bacteria will be assessed in three systems; an artificial in vitro model, an ex vivo skin infection surrogate assay using pig skin and in an in vivo murine model. The purpose of this study is to determine the efficacy of the novel compounds in in vitro and ex vivo models and in vivo models, which will ideally predict the effectiveness of the novel compounds in treating bacterial infections.